An announcement from Can-Fite BioPharma ( (CANF) ) is now available.
On March 20, 2025, Can-Fite BioPharma Ltd. announced that its partner Vetbiolix is advancing the development of Piclidenoson with a new clinical trial for canine osteoarthritis, a market valued at $3.8 billion. This initiative could lead to significant revenue for Can-Fite, with potential royalties and upfront payments projected to reach $325 million over the next decade, assuming a 2029 launch. Piclidenoson offers a potentially safer alternative to current treatments, which are limited by side effects. The development highlights Can-Fite’s strategic positioning in the veterinary market, leveraging shorter regulatory timelines and a growing demand for pet therapeutics.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is engaged in advanced clinical stage drug development, with a platform technology aimed at multi-billion-dollar markets, including treatments for cancer, liver, and inflammatory diseases. Its lead drug candidate, Piclidenoson, has shown promise in a Phase III trial for psoriasis, while another drug, Namodenoson, is being evaluated for hepatocellular carcinoma and other cancers.
YTD Price Performance: -9.05%
Average Trading Volume: 190,079
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $17.56M
Find detailed analytics on CANF stock on TipRanks’ Stock Analysis page.